AstraZeneca Plans To Drug The Undruggable With Scorpion Partnership
Pays $75m Upfront
Executive Summary
The UK major will work with the US biotech to develop up to three precision medicines targeting cancer proteins previously thought undruggable via conventional methods.
You may also be interested in...
Scorpion Partners Two Assets With Pierre Fabre To Prioritize Investment In A Third
The oncology start-up signed a co-development and commercialization agreement with the French pharmaceutical company for two next-generation EGFR inhibitors.
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance
The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.